Quick Answer
Senti Biosciences Holdings, Inc. reported Total Revenue of $22.0 thousand for fiscal year 2025.
Senti Biosciences Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $22.0K | $0.00 -100.0% |
$2.56M -40.2% |
$4.29M +55.2% |
$2.76M | — |
| Revenue (ASC 606) | $22.0K | $0.00 -100.0% |
$1.98M -39.8% |
$3.29M +43.4% |
$2.29M | — |
| Net Income | -$61.44M -16.4% |
-$52.79M +25.7% |
-$71.06M -22.1% |
-$58.21M -5.2% |
-$55.32M | — |
| Diluted EPS | -$2.73 +77.3% |
-$12.03 +24.9% |
-$16.01 -617.9% |
-$2.23 +88.3% |
-$19.00 | — |
| Total Assets | $51.22M -47.6% |
$97.84M -18.1% |
$119.48M -33.9% |
$180.79M +87.0% |
$96.70M | — |
| Cash and Equivalents | $16.42M -66.0% |
$48.28M +34.4% |
$35.93M -37.7% |
$57.62M | $0.00 | — |
| Stockholders Equity | $5.59M -78.2% |
$25.65M -61.7% |
$66.91M -47.4% |
$127.26M | $0.00 +100.0% |
-$58.71M |
| R&D Expense | $37.59M +9.4% |
$34.36M +6.9% |
$32.15M +14.2% |
$28.14M +28.2% |
$21.96M | — |
| Operating Income | -$68.78M -12.7% |
-$61.04M +34.2% |
-$92.73M -49.4% |
-$62.08M -53.5% |
-$40.45M | — |
| Shares Outstanding | 30.88M +539.5% |
4.83M +5.7% |
4.57M -89.5% |
43.37M +1359.0% |
2.97M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$18.13M | +37.2% | -23.0% |
| Diluted EPS | September 30, 2025 | -$0.69 | +89.1% | -23.2% |
| Total Assets | September 30, 2025 | $52.69M | -8.7% | -23.1% |
| Cash and Equivalents | September 30, 2025 | $12.24M | +16.8% | -43.3% |
| Stockholders Equity | September 30, 2025 | $8.12M | -49.2% | -67.1% |
| R&D Expense | September 30, 2025 | $10.52M | +21.5% | +4.9% |
| Operating Income | September 30, 2025 | -$16.95M | -11.4% | -0.9% |
| Shares Outstanding | September 30, 2025 | 26.29M | +473.2% | +0.5% |
- Senti Biosciences Holdings, Inc. reported Total Revenue of $22.0 thousand for fiscal year 2025.
- Senti Biosciences Holdings, Inc. reported Revenue (ASC 606) of $22.0 thousand for fiscal year 2025.
- Senti Biosciences Holdings, Inc. reported Net Income of -$61.44 million for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -16.4% in Net Income compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported Diluted EPS of $2.73 per share (loss) for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed an increase of +77.3% in Diluted EPS compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported Total Assets of $51.22 million for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -47.6% in Total Assets compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported Cash and Equivalents of $16.42 million for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -66.0% in Cash and Equivalents compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported Stockholders Equity of $5.59 million for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -78.2% in Stockholders Equity compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported R&D Expense of $37.59 million for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed an increase of +9.4% in R&D Expense compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported Operating Income of -$68.78 million for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -12.7% in Operating Income compared to the prior fiscal year.
- Senti Biosciences Holdings, Inc. reported Shares Outstanding of 30.88 million shares for fiscal year 2025.
- Senti Biosciences Holdings, Inc. showed an increase of +539.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: